Clinical trialPhase 2Terminated
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients
A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Abraxane® With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer
- Outcome
- Stopped early
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- November 2011
- Expected end
- June 2015
- Enrollment
- 60 participants
- Sites
- 16
- Primary outcomes
- Number of Patients who Achieved Progression-Free Survival
- Sponsor
- Industry
- Results posted
- No
- Last update
- 6 June 2022
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try